Intra-Cellular Therapies (ITCI) PT Raised to $103 at RBC Capital
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $103.00 (from $96.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
